Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Nichi-Iko’s Toyama Plant Gets Back Online as Suspension Order Lifted
Nichi-Iko Pharmaceutical is resuming its manufacturing operations at its major plant in Toyama Prefecture from April 6 as a 32-day business suspension order expired. The Toyama prefectural government told Jiho on April 5 that it is allowing the factory to…
To read the full story
Related Article
- Nichi-Iko Recalls 2 Products over Quality Issues Days after Biz Suspension Lifted
April 9, 2021
- Nichi-Iko Starting Marketing Operations from March 29
March 29, 2021
- Nichi-Iko Plant Probed before Lifting of Biz Suspension Order
March 25, 2021
- Nichi-Iko Chief Apologizes for GMP Violations, but Draws Clear Distinction from Kobayashi Kako Case
March 4, 2021
- Nichi-Iko Ordered to Suspend Biz over Sloppy Manufacturing
March 3, 2021
REGULATORY
- LDP Health Chief Demands CEA Overhaul, Backs Freeze on Price Cuts
October 20, 2026
- Japan Eyes Spring 2027 Plan to Address Drug Discovery Workforce Needs
October 19, 2026
- Minister Lauds Stemirac after Panel Backs Full Approval
October 19, 2026
- CEA Expansion Could Make Drug Price Premiums a Liability: JPMA Official
October 16, 2026
- Nipro’s Stemirac Nears 1st Full Nod Conversion for Regenerative Therapy
October 16, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…